ClinicalTrials.gg
Not yet recruitingNCT07944222Updated Nov 18, 2026

PIONEER: POLR2 Investigation Of Natural History, OutcomEs, and Evaluation for Research

An observational study in POLR2A Mutation, POLR2B Mutation and Neurodevelopmental Disorder (Diagnosis), sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Mayo Clinic · Observational

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 100 studies in Neurodevelopmental Disorders with a site in United States — 37 open to participants now, 53 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.

Planned enrollment
21st of 40
150 · median 158
Started
2026
with 10 others
Observational
40 of 100
19 open now
Primary completion
2027-12
later than 30 of 52 live
Registered
100th of 100
by date

Among the 100 studies in Neurodevelopmental Disorders with a site in United States, this one is the 21st largest by planned enrollment of the 40 observational ones that give a count, is one of 11 that started in 2026, is one of 40 observational ones, reaches primary completion later than 30 of the 52 other live ones, and was the 100th registered.

Neurodevelopmental Disorders

355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.

Browse Neurodevelopmental Disorders studies →

Open to participants now

37 of the 100 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Neurodevelopmental Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to study the natural history of patients with POLR2A or POLR2B variants to enable better understanding of the disorder, with the long-term goal of helping researchers plan future treatment studies.

03

Conditions studied

  • POLR2A Mutation
  • POLR2B Mutation
  • Neurodevelopmental Disorder (Diagnosis)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with pathogenic variants in the POLR2A or POLR2B gene

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically confirmed POLR2 (A or B) genetic mutation OR
  • Suspected POLR2 (A or B) genetic mutation OR
  • Pending results for POLR2 (A or B) genetic mutation
  • May be included if deemed primary caregiver of affected and consented subject (caregiver subject population only, above three criteria do not apply)

Exclusion criteria

Exclusion Criteria:

  • No clinically confirmed POLR2 genetic mutation
  • Patient or family members (Legally authorized representative, if applicable) unable/unwilling to provide or assent.
  • Unable or unwilling to complete blood draw for the research study
  • Not deemed a primary caregiver by the study team (caregiver subject population only, above three criteria do not apply)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Affected participant

    Affected participant, with anticipated or confirmed POLR2 genetic mutation

06

What researchers measure

Primary outcomes

  1. Define POLR2-related neurodevelopmental disorder

    Describe the spectrum, frequency, age of onset, severity, and longitudinal evolution of clinical features, management, and outcomes in individuals with POLR2A or POLR2B related disorders.

    Time frame: 3-years

Secondary outcomes

  1. Disease progression

    To define longitudinal trajectories of disease progression using both non-concurrent data, including historical medical records, diagnostic reports, imaging, laboratory results, genetic testing reports, and other standard-of-care data, and concurrent data collected prospectively through real-world follow-up, clinical assessments, and biospecimen collection.

    Time frame: 3-years

  2. Genotype-phenotype correlations

    To establish genotype-phenotype correlations based on the affected gene, variant type, variant location, inheritance pattern, predicted molecular consequence, and clinical severity.

    Time frame: 3-years

  3. Characterize comorbidities

    To characterize the prevalence, severity, age of onset, and clinical impact of medical comorbidities and organ-system involvement.

    Time frame: 3-years

  4. Describe clinical care

    To describe clinical management patterns, healthcare utilization, surveillance practices, supportive interventions, quality-of-care indicators, and variability or gaps in care.

    Time frame: 3-years

  5. Evaluate associations in disease management and outcomes

    To evaluate associations between management strategies and clinical outcomes in an observational framework.

    Time frame: 3-years

  6. Identify outcomes for interventional clinical trials

    To identify candidate clinical outcome assessments, patient- and caregiver-reported outcomes, functional measures, disease milestones, biomarkers, and endpoints that may support future interventional clinical trials.

    Time frame: 3-years

  7. Registry formation

    To develop and maintain a coded registry of individuals with POLR2-related neurodevelopmental disorder to support longitudinal follow-up, future recontact, recruitment for research studies, and clinical trial readiness.

    Time frame: 3-years

  8. Test standardized clinical outcome assessments

    To evaluate the feasibility, tolerability, and longitudinal utility of standardized developmental, rehabilitation, gait, neuropsychological, adaptive behavior, and quality-of-life measures as candidate clinical outcome assessments for POLR2-related neurodevelopmental disorder.

    Time frame: 3-years

  9. Characterize physical and rehabilitation impacts

    To characterize motor function, manual dexterity, gait, mobility, adaptive behavior, cognition, participation, and caregiver/family impact over a 2-3 year follow-up period.

    Time frame: 3-years

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Participants may be recruited by Mayo Clinic physicians or other study staff. Recruitment may also be supported through Dr. Craig Kaplan's University of Pittsburgh registry, "POLR2A and related POLR2 Patient Registry." Dr. Kaplan may serve as an external referring provider because of his involvement in POLR2 research. Any sharing of participant-identifying information between Mayo Clinic and the University of Pittsburgh will occur only as permitted by participant consent/authorization and under an appropriate data use or similar agreement. Professor William Murphy, an external collaborator in Biomedical Engineering at the University of Wisconsin, may receive coded human biospecimens to support organoid development and related gene-delivery or therapeutic research. Any transfer of specimens or associated information will occur only under appropriate institutional agreements and in accordance with participant consent/authorization. Participants who do not consent to sharing informat

Supporting information: Study protocol, Informed consent form

Time frame: Start date of data sharing is 01/01/2027, until data collection has ceased.

Access criteria: Identifiable information (PHI) will be shared with Crag Kaplan and the University of Pittsburgh Registry. Samples and non-identifiable information will be shared with William Murphy and University of Wisconsin

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 67 non-industry observational studies under Neurodevelopmental Disorders, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 101. This study's planned 13 months is below that.

Counting every sponsor, half of 70 studies reached it within 59 months; a quarter within 32 and three quarters within 101.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Nov 18, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Apr 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944222
Lead sponsor
Mayo Clinic
Responsible party
Radhika Dhamija (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 18, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

POLR2 Research Team
Contact
RSTPOLR2Study@mayo.edu
507-538-6151
Radhika Dhamija, MBBS
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion